A Phase 1, Randomized, Single-blind, Placebo-Controlled, Single Ascending Dose, Safety, Tolerability and Pharmacokinetics Study of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C).
Phase of Trial: Phase I
Latest Information Update: 06 Oct 2013
At a glance
- Drugs ALN PCS (Primary)
- Indications Hypercholesterolaemia
- Focus Adverse reactions; Pharmacogenomic
- 06 Oct 2013 Results published in the Lancet.
- 01 Aug 2012 Status changed from active, no longer recruiting to completed.
- 20 Apr 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History